# BrainSense Adaptive DBS **Entity class:** Medical device and therapy **Domain:** Closed-Loop Neuromodulation / Deep Brain Stimulation **Doc Type:** Device Node **Maturity:** Commercial (United States and Europe) **Collection:** [[collections/Neurotech|Neurotech]] **Primary Sources:** [[research/Research Inferences|Research Inferences]] (INF-0061 to INF-0068) ## Definition **BrainSense Adaptive DBS is [[wiki/Medtronic|Medtronic]]'s closed-loop deep-brain-stimulation therapy for Parkinson's disease, which reads local field potentials from the patient's brain and adjusts stimulation in real time.** The FDA approved it on 24 February 2025 together with the BrainSense Electrode Identifier. It runs on Medtronic's Percept PC and Percept RC neurostimulators, carried by more than 40,000 patients (company figure, February 2025); switching an existing patient from continuous to adaptive stimulation is a software update with no further surgery. ## Evidence - **ADAPT-PD:** a randomized crossover study comparing chronic single- and dual-threshold adaptive modes with continuous DBS, in clinic and home settings, with Helen Bronte-Stewart of Stanford as global principal investigator. The register records 68 patients over a year; that enrollment figure awaits confirmation against the trial publication. - **ADAPT-START:** chronic aDBS findings and programming principles published in *npj Parkinson's Disease* (2026). - **Electrode Identifier:** automated electrode selection that the register records as cutting initial programming time by 85%. ## Forward Capability BrainSense is the approved, reimbursed, continuously running closed control loop inside human brains that the continuity literature often treats as speculative. Because it activates on an installed fleet by software, its adoption curve follows a release cadence rather than a surgical schedule. Each validated biomarker extends the same hardware to a new condition, and each automated programming step moves a portion of clinical judgment into the manufacturer's model. ## Open Questions - The number of patients running adaptive mode in 2026. - Whether adaptive sensing is extended to indications beyond Parkinson's disease, such as epilepsy or depression. - Retention and use of fleet neural telemetry (INF-0072). ## Research Inferences These entries translate the forward-looking register in [[research/Research Inferences|Research Inferences]] into ordinary wiki prose. The tier labels apply to the inference, not automatically to every factual anchor inside it. Proposed IDs above INF-0500 and tier recommendations come from the 2026-10-23 cycle: [[research/Research Inferences Integration Report - 2026-10-23|Research Inferences Integration Report — 2026-10-23]] · [[research/Research Inferences Integration Audit - 2026-10-23|Research Inferences Integration Audit — 2026-10-23]]. - **INF-0061 — Established.** More than 40,000 patients carry Medtronic Percept devices, making adaptive DBS the largest commercial deployment of brain-computer interface technology that has ever existed. The installed base of sensing neural implants is already measured in tens of thousands, and it is clinical rather than experimental. - **INF-0062 — Established.** BrainSense reads local field potentials and adjusts stimulation in real time, which is a closed control loop running continuously inside a human brain, approved and reimbursed. The architecture the continuity literature describes as speculative is in commercial distribution under a movement-disorder indication. - **INF-0063 — Strongly indicated.** ADAPT-PD evaluated adaptive stimulation in clinical *and home* settings across 68 patients over a year, which means the dataset includes unsupervised daily life. Continuous neural telemetry outside the clinic is the precondition for every longitudinal model of a person's neural state. - **INF-0064 — Analytic.** Cutting initial programming time by 85% through automated electrode selection moves clinical judgment into an algorithm. Each such move raises the fraction of the therapy defined by the manufacturer's model rather than by the attending physician, which is a governance shift dressed as a workflow improvement. - **INF-0068 — Analytic.** Adaptive stimulation conserves battery because it stimulates only when required, which extends device life and reduces replacement surgeries. Every efficiency gain in duty cycle translates directly into dwell time, and dwell time is the currency of continuity hardware. - **INF-0070 — Plausible.** A device that continuously tunes itself to an individual's fluctuating state is maintaining a personal model that no clinician possesses. Over years, that model becomes a more detailed record of the person's neural dynamics than any medical record, and its custody is unaddressed. ## Relationships - **manufactured_by:** [[wiki/Medtronic|Medtronic]]. - **validated_by:** Helen Bronte-Stewart (ADAPT-PD global principal investigator) · [[wiki/Stanford University|Stanford University]]. - **indication:** [[wiki/Parkinson's Disease|Parkinson's Disease]]. - **instance_of:** [[wiki/Closed-Loop Neuromodulation|Closed-Loop Neuromodulation]] · [[wiki/Closed-Loop BCI|Closed-Loop BCI]]. - **cluster_home:** [[wiki/Distributed Biological Interfaces|Distributed Biological Interfaces]]. - **ecosystem:** [[wiki/Brain-Computer Interfaces|Brain-Computer Interfaces]] · [[wiki/Neurotechnology Ecosystem|Neurotechnology Ecosystem]] · [[collections/Neurotech|Neurotech]]. ## Sources - [Medtronic earns U.S. FDA approval for the world's first Adaptive deep brain stimulation system — Medtronic, 24 February 2025](https://news.medtronic.com/2025-02-24-Medtronic-earns-U-S-FDA-approval-for-the-worlds-first-Adaptive-deep-brain-stimulation-system-for-people-with-Parkinsons) - [Medtronic earns US FDA approval of "world's first" adaptive DBS system — NeuroNews International, February 2025](https://neuronewsinternational.com/medtronic-earns-us-fda-approval-of-worlds-first-adaptive-dbs-system-for-parkinsons/) - [Chronic adaptive deep brain stimulation in Parkinson's disease: ADAPT-START findings — npj Parkinson's Disease, 2026](https://www.nature.com/articles/s41531-026-01269-z) As of 23 October 2026.